The report highlights that a majority of the companies established their presence in the Indian market within the past five years. This underscores the country’s rapidly growing role in pharmaceutical research, innovation, and value creation.
“Our analysis highlights how India has rapidly evolved from a support base to the very center of innovation for global pharma and healthcare. In just five years, GCC penetration in enabling functions like finance, HR, supply chain, and IT has crossed about 60 per cent,” said Arindam Sen, Partner and GCC Sector Lead – Technology, Media & Entertainment and Telecommunications, EY India.
Notably, the life sciences GCCs have rapidly evolved from traditional back-office roles into strategic innovation engines, reported IANS.
Far from being limited to support functions, these centers now play a critical role in global mandates such as drug discovery, digital therapeutics, and real-world evidence (RWE) analytics, increasingly leveraging artificial intelligence to accelerate pipelines and drive patient-centric innovation, the report said.
"But what truly stands out is the deepening role in core functions -- from drug discovery and regulatory affairs to medical and commercial operations," Sen added.
Further, the analysis showed that penetration across both enabling and core functions has accelerated sharply in the last five years.
On the enabling side, life sciences GCCs in India now handle 70 per cent of finance, 75 per cent of HR, 62 per cent of supply chain, and 67 per cent of IT functions for their global life sciences firms.
More significantly, their role in core functions has deepened -- with 45 per cent penetration in drug discovery and development, 60 per cent in regulatory affairs, 54 per cent in medical affairs, and 50 per cent in commercial operations.
This shift underlines India’s transition from a support hub to a strategic center powering end-to-end innovation and operations for the industry.
“This isn’t about cost arbitrage anymore; it’s about India becoming indispensable to the global R&D pipeline. Lifesciences multinationals are embedding their most strategic, knowledge-intensive work here, making India the epicentre for life sciences innovation, compliance, and future growth,” Sen said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.